前列腺癌的临床前成像
本文综述前列腺癌临床前成像模型与分子探针开发。SPECT和PET探针需在临床前模型中评估并经FDA等监管机构批准后方可临床转化。人异种移植瘤模型仍是主力,但动物模型构建面临实际挑战,PET/SPECT分辨率受衰减过程限制约0.5 cm。
要点
- 分子成像探针临床转化前需在临床前模型评估并经FDA等监管机构批准。
- 人异种移植瘤模型仍是临床前动物模型的主力。
- PET和SPECT衰减过程固有分辨率限制约0.5 cm。
核心结论
- 将分子成像探针转化至临床前,需先在临床前模型中评估,并经FDA及其他监管机构批准后方可临床采用。
- 最佳动物模型被采用、接受和科学验证,是这一跨学科方法应对前列腺癌的重要组成部分。
研究设计与样本
- 综述,检索范围未在原文中报告。
主要发现
- 前列腺癌仍是主要死亡和发病原因,影响数百万男性,很大比例在高龄时预计会发病。
- 过去约50年治疗和管理进展显著,诊断成像技术多重进步是其中一方面。
- 分子成像技术具有高灵敏度和特异性,能更准确评估疾病状态并更早检测复发。
- 成熟雄性动物中前列腺癌自然不发生、在免疫健全动物中难以诱发疾病、人与啮齿类等较小动物体型差异大,是构建可重复稳健人类疾病动物模型的实际问题。
- 人异种移植瘤模型在无胸腺免疫缺陷小鼠中的研究一直是、且仍是临床前动物模型的主力。
关键数值与推荐
- PET和SPECT衰减过程的固有分辨率灵敏度限制从根本上设定在约0.5 cm分辨率极限。
临床怎么用
- 原文未据此给出推荐。
局限性
- 构建可重复且稳健的人类疾病动物模型面临实际问题,包括成熟雄性动物中前列腺癌自然不发生。
- 在免疫健全动物中诱发疾病困难。
- 人与方便使用的较小动物如啮齿类之间体型差异大。
- 理想方案与可实现方案之间不得不做出妥协。
- 小动物中基于放射测量的研究与分子模型结合始终受空间限制,因PET和SPECT衰减过程固有分辨率灵敏度限制约0.5 cm。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate cancer remains a major cause of mortality and morbidity, affecting millions of men, with a large percentage expected to develop the disease as they reach advanced ages. Treatment and management advances have been dramatic over the past 50 years or so, and one aspect of these improvements is reflected in the multiple advances in diagnostic imaging techniques. Much attention has been focused on molecular imaging techniques that offer high sensitivity and specificity and can now more accurately assess disease status and detect recurrence earlier. During development of molecular imaging probes, single-photon emission computed tomography (SPECT) and positron emission tomography (PET) must be evaluated in preclinical models of the disease. If such agents are to be translated to the clinic, where patients undergoing these imaging modalities are injected with a molecular imaging probe, these agents must first be approved by the FDA and other regulatory agencies prior to their adoption in clinical practice. Scientists have worked assiduously to develop preclinical models of prostate cancer that are relevant to the human disease to enable testing of these probes and related targeted drugs. Challenges in developing reproducible and robust models of human disease in animals are beset with practical issues such as the lack of natural occurrence of prostate cancer in mature male animals, the difficulty of initiating disease in immune-competent animals and the sheer size differences between humans and conveniently smaller animals such as rodents. Thus, compromises in what is ideal and what can be achieved have had to be made. The workhorse of preclinical animal models has been, and remains, the investigation of human xenograft tumor models in athymic immunocompromised mice. Later models have used other immunocompromised models as they have been found and developed, including the use of directly derived patient tumor tissues, completely immunocompromised mice, orthotopic methods for inducing prostate cancer within the mouse prostate itself and metastatic models of advanced disease. These models have been developed in close parallel with advances in imaging agent chemistries, radionuclide developments, computer electronics advances, radiometric dosimetry, biotechnologies, organoid technologies, advances in in vitro diagnostics, and overall deeper understandings of disease initiation, development, immunology, and genetics. The combination of molecular models of prostatic disease with radiometric-based studies in small animals will always remain spatially limited due to the inherent resolution sensitivity limits of PET and SPECT decay processes, fundamentally set at around a 0.5 cm resolution limit. Nevertheless, it is central to researcher's efforts and to successful clinical translation that the best animal models are adopted, accepted, and scientifically verified as part of this truly interdisciplinary approach to addressing this important disease.
引用
- Olkowski C, Fernandes B, Griffiths GL, et al. Preclinical Imaging of Prostate Cancer. Semin Nucl Med. 2023. PMID: 36882335. doi:10.1053/j.semnuclmed.2023.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。